CTOs on the Move

uniPHARM Wholesale Drugs

www.unipharm.com

 
uniPHARM Wholesale Drugs Ltd. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.unipharm.com
  • 2051 Van Dyke Pl
    Richmond, BC CAN V6V 1X6
  • Phone: 604.270.9745

Executives

Name Title Contact Details

Similar Companies

Newport Healthcare

Newport Healthcare is changing the face of behavioral health services for teens, young adults and their families by providing sustainable healing.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

Horizon Behavioral Health

Behavioral health, Recovery, drug, rehabilitation, mental illness, depression, Appomattox, Appomattox County, Virginia, Central Virginia, alcoholism, Alcohol

CAREstream America

Specializing in Respiratory, Patient Monitoring, Diagnostic, Anesthesia, Ventilation Biomedical and Plastic Surgery Products.